WO2007118996A3 - Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme médicament pour le traitement symptomatique de la mucoviscidose - Google Patents

Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme médicament pour le traitement symptomatique de la mucoviscidose Download PDF

Info

Publication number
WO2007118996A3
WO2007118996A3 PCT/FR2007/000582 FR2007000582W WO2007118996A3 WO 2007118996 A3 WO2007118996 A3 WO 2007118996A3 FR 2007000582 W FR2007000582 W FR 2007000582W WO 2007118996 A3 WO2007118996 A3 WO 2007118996A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucoviscidosis
inhibitor
medicine
symptomatic treatment
cytosolic phospholipase
Prior art date
Application number
PCT/FR2007/000582
Other languages
English (en)
Other versions
WO2007118996A2 (fr
Inventor
Fariel Dif
Lhousseine Touqui
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Fariel Dif
Lhousseine Touqui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med, Fariel Dif, Lhousseine Touqui filed Critical Pasteur Institut
Priority to US12/295,965 priority Critical patent/US20100093985A1/en
Priority to JP2009503616A priority patent/JP2009532445A/ja
Priority to CA002648239A priority patent/CA2648239A1/fr
Priority to EP07731257A priority patent/EP2001454A2/fr
Publication of WO2007118996A2 publication Critical patent/WO2007118996A2/fr
Publication of WO2007118996A3 publication Critical patent/WO2007118996A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet l'utilisation d'au moins un inhibiteur de la phospholipase A2 cytosolique (cPLA2) dans la préparation d'un médicament destiné au traitement symptomatique préventif et/ou curatif de la mucoviscidose particulièrement de la sécrétion accrue de mucus dans la mucoviscidose.
PCT/FR2007/000582 2006-04-06 2007-04-05 Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme médicament pour le traitement symptomatique de la mucoviscidose WO2007118996A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/295,965 US20100093985A1 (en) 2006-04-06 2007-04-05 Use of at least one cytosolic phospholipase a2 inhibitor as a medicine for symptomatic treatment of mucoviscidosis
JP2009503616A JP2009532445A (ja) 2006-04-06 2007-04-05 嚢胞性線維症の対症療法のための少なくとも１の細胞質ホスホリパーゼａ２阻害剤の使用
CA002648239A CA2648239A1 (fr) 2006-04-06 2007-04-05 Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement symptomatique de la mucoviscidose
EP07731257A EP2001454A2 (fr) 2006-04-06 2007-04-05 Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme médicament pour le traitement symptomatique de la mucoviscidose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0603059 2006-04-06
FR0603059A FR2899471A1 (fr) 2006-04-06 2006-04-06 Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement des maladies respiratoires

Publications (2)

Publication Number Publication Date
WO2007118996A2 WO2007118996A2 (fr) 2007-10-25
WO2007118996A3 true WO2007118996A3 (fr) 2008-04-10

Family

ID=37441809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000582 WO2007118996A2 (fr) 2006-04-06 2007-04-05 Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme médicament pour le traitement symptomatique de la mucoviscidose

Country Status (6)

Country Link
US (1) US20100093985A1 (fr)
EP (1) EP2001454A2 (fr)
JP (1) JP2009532445A (fr)
CA (1) CA2648239A1 (fr)
FR (1) FR2899471A1 (fr)
WO (1) WO2007118996A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031763A1 (fr) 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Utilisation d'inhibiteurs de phospholipase a2 pour traiter ou prévenir une infection à flavivirus
GB201806663D0 (en) * 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
CN114767859A (zh) * 2022-04-11 2022-07-22 山东大学齐鲁医院 靶向cPLA2在放射诱导的肺损伤防治中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
WO2002060535A1 (fr) * 2001-01-31 2002-08-08 Leff Alan R Procede permettant de traiter les etats inflammatoires en inhibant la phospholipase a2 cytosolique
WO2003048122A2 (fr) * 2001-12-03 2003-06-12 Wyeth Inhibiteurs de phospholipase a2 cytosolique
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006214384A1 (en) * 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
WO2002060535A1 (fr) * 2001-01-31 2002-08-08 Leff Alan R Procede permettant de traiter les etats inflammatoires en inhibant la phospholipase a2 cytosolique
WO2003048122A2 (fr) * 2001-12-03 2003-06-12 Wyeth Inhibiteurs de phospholipase a2 cytosolique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIRSCHNEK SUSANNE ET AL: "Phospholipase A(2) functions in Pseudomonas aeruginosa-induced apoptosis", INFECTION AND IMMUNITY, vol. 74, no. 2, February 2006 (2006-02-01), pages 850 - 860, XP002409913, ISSN: 0019-9567 *
MALAVIYA ET AL: "Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 539, no. 3, 20 March 2006 (2006-03-20), available online 20 March 2006, pages 195 - 204, XP005465787, ISSN: 0014-2999 *
NAGASE TAKAHIDE ET AL: "A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 284, no. 5 Part 1, May 2003 (2003-05-01), pages L720 - L726, XP008072144, ISSN: 0002-9513 *
NETTESHEIM PAUL ET AL: "Tumor necrosis factor alpha stimulates arachidonic acid metabolisms and mucus production in rat tracheal epithelial cell cultures", TOXICOLOGY LETTERS (SHANNON), vol. 88, no. 1-3, 1996, pages 35 - 37, XP002409914, ISSN: 0378-4274 *

Also Published As

Publication number Publication date
JP2009532445A (ja) 2009-09-10
US20100093985A1 (en) 2010-04-15
WO2007118996A2 (fr) 2007-10-25
EP2001454A2 (fr) 2008-12-17
CA2648239A1 (fr) 2007-10-25
FR2899471A1 (fr) 2007-10-12

Similar Documents

Publication Publication Date Title
WO2007127263A3 (fr) Utilisations thérapeutiques d'urolithines
WO2007117971A3 (fr) Traitements de l'allergie oculaire
WO2009001097A3 (fr) Thérapie par réduction de substrat
WO2007036363A8 (fr) Ester d'acide butyrique d'hydrate de carbone et de polyols d'hydrate de carbone
WO2007115305A3 (fr) Formes de dosage orales incluant un inhibiteur de l'agrégation plaquettaire et un inhibiteur acide
WO2006138475A3 (fr) Inhibiteurs de mao-b utilises pour le traitement de l'obesite
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2009027346A3 (fr) Inhibiteurs 17bêta-hydroxystéroïd-déhydrogénase de type 1 pour traiter des maladies hormono-dépendantes
WO2008012555A3 (fr) Thérapie par réduction d'épitopes
WO2009072604A1 (fr) Anticorps anti-nr10 et son utilisation
WO2006122186A3 (fr) Derives de 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone utilises dans le traitement de l'hypercholesterolemie
WO2009064458A3 (fr) Compositions pour le traitement de l'inflammation des voies gastro-intestinales
WO2009071219A3 (fr) Comprimé dispersible oral
WO2007072169A3 (fr) Combinaison pharmaceutique utilisee pour traiter des troubles urinaires du bas appareil (tuba)
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
WO2008004228A3 (fr) systèmes endoscopiques
WO2007056279A3 (fr) Inhibiteurs de phospholipases, notamment inhibiteurs de phospholipases multivalents, leur utilisation, notamment en tant qu'inhibiteurs de phospholipases localises dans une lumiere
PL2046541T3 (pl) Urządzenie do wprowadzania nacięć osłabiających na folię lub skórę
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2008054808A3 (fr) Compositions pharmaceutiques d'elvucitabine
WO2007057201A3 (fr) Composition pharmaceutique exempte de dexpanthenol, d'ions calcium et de phosphate, utilisation de chelateurs du calcium et d'un regulateur de viscosite acceptable sur le plan ophtalmique
WO2007140317A3 (fr) Méthodes d'utilisation d'inhibiteurs de la phospholipase a2 cytosolique dans le traitement de la thrombose
WO2008079303A3 (fr) Détection de rejet d'organe
WO2008020904A3 (fr) Procédé pour réduire le risque ou pour la prévention d'une infection due a des opérations chirurgicales ou médicales invasives
WO2008016640A3 (fr) Traitement de l'insuffisance cardiaque progressive chronique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731257

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007731257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 8303/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2648239

Country of ref document: CA

Ref document number: 2009503616

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12295965

Country of ref document: US